Cytokinetics' Heart Drug Shows Promising Results in Recent Studies
TL;DR Summary
A new drug from Cytokinetics, aficamten, showed improved exercise capacity over the common beta blocker metoprolol in a Phase 3 study for patients with hypertrophic cardiomyopathy, potentially accelerating its FDA approval and broader use.
- Cytokinetics drug yielded benefits over common therapy in patients with heart condition, study shows statnews.com
- Cytokinetics says heart drug data should 'turn heads' on standard of care Endpoints News
- Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine Yahoo Finance
- Cytokinetics to Participate in September Investor Conferences GlobeNewswire
- Novel Oral Agent Proves Mettle in Obstructive Hypertrophic Cardiomyopathy MedPage Today
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
85%
230 → 34 words
Want the full story? Read the original article
Read on statnews.com